Focus

antibody drug

LATEST

US News
US News

FDA Pulls Authorization for Evusheld, Says It’s Ineffective Against New COVID Mutations

FDA Pulls Authorization for Evusheld, Says It’s Ineffective Against New COVID Mutations
|
AMERICA
AMERICA

AstraZeneca’s COVID-19 Prevention Drug Granted Emergency Authorization for Immune Compromised

AstraZeneca’s COVID-19 Prevention Drug Granted Emergency Authorization for Immune Compromised
|
PUBLIC HEALTH INFORMATION
PUBLIC HEALTH INFORMATION

FDA Grants Eli Lilly’s Experimental COVID-19 Antibody-Drug Emergency Use Authorization

FDA Grants Eli Lilly’s Experimental COVID-19 Antibody-Drug Emergency Use Authorization
|
US News
US News

US to Pay Eli Lilly $375 Million for 300,000 Vials of Experimental COVID-19 Antibody Drug

US to Pay Eli Lilly $375 Million for 300,000 Vials of Experimental COVID-19 Antibody Drug
|
US News
US News

FDA Pulls Authorization for Evusheld, Says It’s Ineffective Against New COVID Mutations

FDA Pulls Authorization for Evusheld, Says It’s Ineffective Against New COVID Mutations
|
AMERICA
AMERICA

AstraZeneca’s COVID-19 Prevention Drug Granted Emergency Authorization for Immune Compromised

AstraZeneca’s COVID-19 Prevention Drug Granted Emergency Authorization for Immune Compromised
|
PUBLIC HEALTH INFORMATION
PUBLIC HEALTH INFORMATION

FDA Grants Eli Lilly’s Experimental COVID-19 Antibody-Drug Emergency Use Authorization

FDA Grants Eli Lilly’s Experimental COVID-19 Antibody-Drug Emergency Use Authorization
|
US News
US News

US to Pay Eli Lilly $375 Million for 300,000 Vials of Experimental COVID-19 Antibody Drug

US to Pay Eli Lilly $375 Million for 300,000 Vials of Experimental COVID-19 Antibody Drug
|